AriBio Press Releases - EIN Presswire - Press Release Distribution Service

Published on August 19, 2026 - 19:17 GMT

AriBio Reports Interim Phase 2a Results for AR1005 in Dementia with Lewy Bodies

Interim analysis shows significant improvement in cognitive fluctuation and favorable quantitative EEG findings, with broader clinical trends favoring AR1005 SEONGNAM-SI, SOUTH KOREA, August 19, 2026 /⁨EINPresswire.com⁩/ -- AriBio Co., Ltd., a clinical- …

Distribution channels: Companies, Education ...

Published on August 3, 2026 - 17:28 GMT

AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial of AR1001 for Early Alzheimer’s Disease

Pivotal Phase 3 registration trial advances to database lock and analysis; Topline results expected in Q4’26; Results planned for presentation at CTAD 2026 SEONGNAM-SI, SOUTH KOREA, August 3, 2026 /⁨EINPresswire.com⁩/ -- AriBio Co., Ltd., a clinical- …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 30, 2026 - 05:05 GMT

AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease

Readout from the pivotal global Phase 3 trial of 1,535 participants is expected later in 2026 SAN DIEGO, CA, UNITED STATES, June 30, 2026 /⁨EINPresswire.com⁩/ -- AriBio Co., Ltd. today announced that the last patient has completed dosing in POLARIS-AD ( …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...